Cost effectiveness of pneumococcal vaccination among Dutch infants:an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

Objectives To update cost effectiveness estimates for the four dose (3+1) schedule of the seven valent pneumococcal conjugated vaccine (PCV-7) in the Netherlands and to explore the impact on cost effectiveness of reduced dose schedules and implementation of 10 valent and 13 valent pneumococcal vaccines (PCV-10 and PCV-13). Design Economic evaluation comparing PCV-7, PCV-10, and PCV-13 with no vaccination using a decision tree analytic model built from data in previous studies. Setting The Netherlands. Population A cohort of 180 000 newborns followed until 5 years of age. Main outcome measures... Mehr ...

Verfasser: Rozenbaum, M.H.
Sanders, E.A.M.
van Hoek, A.J.
Jansen, A.G.S.C.
van der Ende, A.
van den Dobbelsteen, G.
Rodenburg, G.D.
Hak, E.
Postma, M.J.
Dokumenttyp: Artikel
Erscheinungsdatum: 2010
Reihe/Periodikum: Rozenbaum , M H , Sanders , E A M , van Hoek , A J , Jansen , A G S C , van der Ende , A , van den Dobbelsteen , G , Rodenburg , G D , Hak , E & Postma , M J 2010 , ' Cost effectiveness of pneumococcal vaccination among Dutch infants : an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines ' , British Medical Journal , vol. 340 , 2509 , pp. Art. No. c2509- . https://doi.org/10.1136/bmj.c2509
Schlagwörter: ACUTE OTITIS-MEDIA / STREPTOCOCCUS-PNEUMONIAE / CHILDREN YOUNGER / DISEASE / IMMUNOGENICITY / PREVENTION / EFFICACY / NETHERLANDS / IMPACT / STATES
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29029023
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/dd74e898-e62d-4db9-9a26-51ae7ffebcc6

Objectives To update cost effectiveness estimates for the four dose (3+1) schedule of the seven valent pneumococcal conjugated vaccine (PCV-7) in the Netherlands and to explore the impact on cost effectiveness of reduced dose schedules and implementation of 10 valent and 13 valent pneumococcal vaccines (PCV-10 and PCV-13). Design Economic evaluation comparing PCV-7, PCV-10, and PCV-13 with no vaccination using a decision tree analytic model built from data in previous studies. Setting The Netherlands. Population A cohort of 180 000 newborns followed until 5 years of age. Main outcome measures Costs; gains in life years and quality adjusted life years (QALYs); and incremental cost effectiveness ratios. Results Under base case assumptions-that is, assuming a five year protective period of the vaccine and no assumed net indirect effects (herd protection minus serotype replacement) among children aged over 5 years-vaccination with PVC-7 in a four dose (3+1) schedule was estimated to prevent 71 and 5778 cases of invasive and non-invasive pneumococcal disease, respectively, in children aged up to 5 years. This corresponds with a total net gain of 173 life years or 277 QALYs. The incremental cost effectiveness ratio of PCV-7 was estimated at (sic)113 891 (98 pound 300; $145 000) per QALY, well over the ratio of (sic)50 000 per QALY required for PCV-7 to be regarded as potentially cost effective. A three dose (2+1) schedule of PCV-7 reduced the incremental cost effectiveness ratio to (sic)82 975 per QALY. For various assumptions and including 10% of the maximum net indirect effects among individuals aged 5 years and over, PCV-10 and PCV-13 had incremental cost effectiveness ratios ranging from (sic)31 250 to (sic)52 947 per QALY. Conclusions The current Dutch infant vaccination programme of four doses of PCV-7 is not cost effective because of increases in invasive disease caused by nonvaccine serotypes, which reduces the overall direct effects of vaccination and offsets potential positive herd protection benefits in ...